Soleno Therapeutics Net Income
| SLNO Stock | USD 41.53 1.95 4.93% |
As of the 9th of February, Soleno Therapeutics has the Coefficient Of Variation of (854.23), variance of 23.37, and Risk Adjusted Performance of (0.09). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Soleno Therapeutics, as well as the relationship between them.
Soleno Therapeutics Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 18.0827 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -158.3 M | -150.4 M | |
| Net Loss | -158.3 M | -150.4 M | |
| Net Loss | -21.7 M | -22.7 M | |
| Net Loss | (3.94) | (4.14) | |
| Net Income Per E B T | 1.01 | 0.87 |
Soleno | Net Income | Build AI portfolio with Soleno Stock |
Evaluating Soleno Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Soleno Therapeutics's fundamental strength.
Latest Soleno Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Soleno Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Soleno Therapeutics financial statement analysis. It represents the amount of money remaining after all of Soleno Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Soleno Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Soleno Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (175.85 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Soleno Net Income Regression Statistics
| Arithmetic Mean | (42,814,608) | |
| Coefficient Of Variation | (134.65) | |
| Mean Deviation | 41,885,050 | |
| Median | (15,908,546) | |
| Standard Deviation | 57,650,457 | |
| Sample Variance | 3323.6T | |
| Range | 172.1M | |
| R-Value | (0.76) | |
| Mean Square Error | 1506.7T | |
| R-Squared | 0.58 | |
| Significance | 0.0004 | |
| Slope | (8,657,063) | |
| Total Sum of Squares | 53177.2T |
Soleno Net Income History
Other Fundumenentals of Soleno Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Soleno Therapeutics Net Income component correlations
Soleno Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Soleno Therapeutics is extremely important. It helps to project a fair market value of Soleno Stock properly, considering its historical fundamentals such as Net Income. Since Soleno Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Soleno Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Soleno Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Soleno diversify its offerings? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Soleno Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Soleno Therapeutics requires distinguishing between market price and book value, where the latter reflects Soleno's accounting equity. The concept of intrinsic value - what Soleno Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Soleno Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Soleno Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Soleno Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Soleno Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Soleno Therapeutics.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Soleno Therapeutics on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Soleno Therapeutics or generate 0.0% return on investment in Soleno Therapeutics over 90 days. Soleno Therapeutics is related to or competes with Praxis Precision, Dyne Therapeutics, Ascentage Pharma, Apogee Therapeutics, Centessa Pharmaceuticals, Xenon Pharmaceuticals, and Ultragenyx. Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization ... More
Soleno Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Soleno Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Soleno Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.14) | |||
| Maximum Drawdown | 26.59 | |||
| Value At Risk | (5.49) | |||
| Potential Upside | 5.4 |
Soleno Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Soleno Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Soleno Therapeutics' standard deviation. In reality, there are many statistical measures that can use Soleno Therapeutics historical prices to predict the future Soleno Therapeutics' volatility.| Risk Adjusted Performance | (0.09) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | (0.50) |
Soleno Therapeutics February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.09) | |||
| Market Risk Adjusted Performance | (0.49) | |||
| Mean Deviation | 3.13 | |||
| Coefficient Of Variation | (854.23) | |||
| Standard Deviation | 4.83 | |||
| Variance | 23.37 | |||
| Information Ratio | (0.14) | |||
| Jensen Alpha | (0.67) | |||
| Total Risk Alpha | (1.05) | |||
| Treynor Ratio | (0.50) | |||
| Maximum Drawdown | 26.59 | |||
| Value At Risk | (5.49) | |||
| Potential Upside | 5.4 | |||
| Skewness | (2.05) | |||
| Kurtosis | 12.26 |
Soleno Therapeutics Backtested Returns
Soleno Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0635, which indicates the firm had a -0.0635 % return per unit of risk over the last 3 months. Soleno Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Soleno Therapeutics' Variance of 23.37, risk adjusted performance of (0.09), and Coefficient Of Variation of (854.23) to confirm the risk estimate we provide. The entity has a beta of 1.15, which indicates a somewhat significant risk relative to the market. Soleno Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, Soleno Therapeutics is expected to follow. At this point, Soleno Therapeutics has a negative expected return of -0.21%. Please make sure to validate Soleno Therapeutics' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Soleno Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.39 |
Poor reverse predictability
Soleno Therapeutics has poor reverse predictability. Overlapping area represents the amount of predictability between Soleno Therapeutics time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Soleno Therapeutics price movement. The serial correlation of -0.39 indicates that just about 39.0% of current Soleno Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.39 | |
| Spearman Rank Test | -0.37 | |
| Residual Average | 0.0 | |
| Price Variance | 5.16 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Soleno Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Soleno Therapeutics reported net income of (175.85 Million). This is 151.53% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 130.8% higher than that of the company.
Soleno Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Soleno Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Soleno Therapeutics could also be used in its relative valuation, which is a method of valuing Soleno Therapeutics by comparing valuation metrics of similar companies.Soleno Therapeutics is currently under evaluation in net income category among its peers.
Soleno Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Soleno Therapeutics from analyzing Soleno Therapeutics' financial statements. These drivers represent accounts that assess Soleno Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Soleno Therapeutics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 604.3M | 163.5M | 83.1M | 1.8B | 1.6B | 1.7B | |
| Enterprise Value | 555.2M | 142.7M | 68.7M | 1.8B | 1.6B | 1.7B |
Soleno Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Soleno Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Soleno Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Soleno Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Soleno Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Soleno Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Soleno Therapeutics' value.| Shares | Holocene Advisors, Lp | 2025-06-30 | 1.2 M | Nantahala Capital Management, Llc | 2025-06-30 | 1 M | Geode Capital Management, Llc | 2025-06-30 | 902.4 K | The Carlyle Group Inc | 2025-06-30 | 861 K | Polar Capital Holdings Plc | 2025-06-30 | 817.5 K | Emerald Advisers, Llc | 2025-06-30 | 672.9 K | Pictet Asset Manangement Sa | 2025-06-30 | 652.1 K | Amvescap Plc. | 2025-06-30 | 646 K | Millennium Management Llc | 2025-06-30 | 633.7 K | Hhg Plc | 2025-06-30 | 5.3 M | Vivo Capital, Llc | 2025-06-30 | 4 M |
Soleno Fundamentals
| Return On Equity | -0.21 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | 0.34 % | ||||
| Current Valuation | 1.78 B | ||||
| Shares Outstanding | 53.71 M | ||||
| Shares Owned By Insiders | 2.00 % | ||||
| Shares Owned By Institutions | 98.00 % | ||||
| Number Of Shares Shorted | 11.47 M | ||||
| Price To Earning | (3.71) X | ||||
| Price To Book | 4.51 X | ||||
| Price To Sales | 22.61 X | ||||
| Gross Profit | 96.84 M | ||||
| EBITDA | (173.63 M) | ||||
| Net Income | (175.85 M) | ||||
| Cash And Equivalents | 24.07 M | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 52.83 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 3.43 X | ||||
| Book Value Per Share | 9.21 X | ||||
| Cash Flow From Operations | (69.1 M) | ||||
| Short Ratio | 7.28 X | ||||
| Earnings Per Share | (1.75) X | ||||
| Target Price | 111.92 | ||||
| Number Of Employees | 152 | ||||
| Beta | -3.18 | ||||
| Market Capitalization | 2.23 B | ||||
| Total Asset | 330.97 M | ||||
| Retained Earnings | (452.26 M) | ||||
| Working Capital | 275.14 M | ||||
| Net Asset | 330.97 M |
About Soleno Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Soleno Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Soleno Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Soleno Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Soleno Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Soleno Stock
Moving against Soleno Stock
| 0.52 | ENGN | enGene Holdings Common | PairCorr |
| 0.5 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.47 | DSGN | Design Therapeutics | PairCorr |
| 0.34 | 63E | ONWARD MEDICAL BV | PairCorr |
The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.
The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Will Biotechnology sector continue expanding? Could Soleno diversify its offerings? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Soleno Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Soleno Therapeutics requires distinguishing between market price and book value, where the latter reflects Soleno's accounting equity. The concept of intrinsic value - what Soleno Therapeutics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Soleno Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Soleno Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.